Payment overview · 2025
General Payments
$146.01
2 reported records · 2 companies
Healthcare provider profile · identity verified
Marcel Benoit, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · BROOKLYN, NY · NPI 1609855725
Verified facts
What the public records show
CMS Open Payments records show Marcel Benoit, MD received $146.01 in general payments during 2025 across 2 reported records.
Phathom Pharmaceuticals, Inc. accounted for 85.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 370 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.82 | 85.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.19 | 14.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.01 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
370 | 99 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 143 |
| Eliquis | Apixaban | 370 | 99 |
| Metformin Hcl | Metformin Hcl | 293 | 103 |
| Gabapentin | Gabapentin | 242 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 96 |
| Ipratropium Bromide | Ipratropium Bromide | 222 | 29 |
| Levetiracetam | Levetiracetam | 218 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 90 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 199 | 34 |
| Albuterol Sulfate | Albuterol Sulfate | 178 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 68 |
| Furosemide | Furosemide | 165 | 78 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 155 | 33 |
| Losartan Potassium | Losartan Potassium | 151 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 70 |
| Lacosamide | Lacosamide | 130 | suppressed |
| Simvastatin | Simvastatin | 129 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 38 |
| Jardiance | Empagliflozin | 126 | 41 |
| Carvedilol | Carvedilol | 112 | 45 |
| Tradjenta | Linagliptin | 110 | 18 |
| Mirtazapine | Mirtazapine | 106 | 53 |
| Finasteride | Finasteride | 102 | 44 |
| Lisinopril | Lisinopril | 101 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 31 |
| Midodrine Hcl | Midodrine Hcl | 95 | 35 |
| Famotidine | Famotidine | 92 | 44 |
| Omeprazole | Omeprazole | 88 | 45 |
| Donepezil Hcl | Donepezil Hcl | 86 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 27 |
| Latanoprost | Latanoprost | 82 | 30 |
| Montelukast Sodium | Montelukast Sodium | 82 | 32 |
| Levofloxacin | Levofloxacin | 81 | 49 |
| Nifedipine Er | Nifedipine | 80 | 34 |
| Labetalol Hcl | Labetalol Hcl | 79 | 20 |
| Meloxicam | Meloxicam | 79 | 39 |
| Januvia | Sitagliptin Phosphate | 78 | 21 |
| Sodium Chloride | 0.9 % Sodium Chloride | 78 | 32 |
| Cefepime Hcl | Cefepime Hcl | 77 | 27 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 77 | suppressed |
| Prednisone | Prednisone | 70 | 28 |
| Trazodone Hcl | Trazodone Hcl | 68 | 27 |
| Tramadol Hcl | Tramadol Hcl | 65 | 18 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 63 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 29 |
| Vancomycin Hcl | Vancomycin Hcl | 62 | 15 |
| Sucralfate | Sucralfate | 61 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | 23 |
| Silodosin | Silodosin | 59 | 15 |
| Santyl | Collagenase Clostridium Hist. | 58 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 22 |
| Entresto | Sacubitril/Valsartan | 56 | 19 |
| Enulose | Lactulose | 56 | 17 |
| Memantine Hcl | Memantine Hcl | 52 | 15 |
| Nystatin | Nystatin | 52 | 32 |
| Scopolamine | Scopolamine | 50 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 46 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 46 | 25 |
| Calcium Acetate | Calcium Acetate | 45 | 12 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 45 | 16 |
| Alendronate Sodium | Alendronate Sodium | 42 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 28 |
| Meropenem | Meropenem | 38 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 14 |
| Xarelto | Rivaroxaban | 37 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 26 |
| Brimonidine Tartrate | Brimonidine Tartrate | 35 | 15 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Pradaxa | Dabigatran Etexilate Mesylate | 35 | suppressed |
| Baclofen | Baclofen | 34 | 14 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 18 |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | 20 |
| Ezetimibe | Ezetimibe | 32 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 14 |
| Glipizide | Glipizide | 31 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 31 | 25 |
| Alogliptin | Alogliptin Benzoate | 30 | 15 |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 17 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 22 |
| Spironolactone | Spironolactone | 29 | 14 |
| Valsartan | Valsartan | 29 | 15 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 18 |
| Torsemide | Torsemide | 28 | 19 |
| Atenolol | Atenolol | 27 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 27 | 15 |
| Risperidone | Risperidone | 27 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 24 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | 13 |
| Admelog | Insulin Lispro | 20 | 12 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Isoniazid | Isoniazid | 20 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | 11 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Epogen | Epoetin Alfa | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Linezolid-D5w | Linezolid In Dextrose 5% | 16 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | 11 |
| Naproxen | Naproxen | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Linezolid | Linezolid | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.01 · 2 records | Phathom Pharmaceuticals, Inc. | VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error